The GLP-1 medication trend has taken the health and wellness world by storm, largely hailed as a game-changer for weight loss ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

A new clinical trial showed promising results in curbing alcohol cravings in individuals with moderate alcohol-use disorder.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for treating diabetes, work by stimulating insulin secretion and suppressing glucagon release, thereby helping regulate blood ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders of pregnancy, gestational diabetes, have a preterm birth or cesarean ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, ...

GLP-1 receptor agonists work on GLP-1 receptors ... Varisco points out that the drug injections ended up reducing the number of drinks people had at a time versus the number of days that people ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may increase the risk of pulmonary aspiration among patients undergoing surgery ...